Galectin-3 is a chimeric
carbohydrate-binding protein, which interacts with cell surface
carbohydrate-containing molecules and extracellular matrix
glycoproteins and has been implicated in various biological processes such as cell growth, angiogenesis, motility, and
metastasis. It is expressed in a wide range of
tumor cells and is associated with
tumor progression. The functions of
galectin-3 are dependent on its localization and post-translational modifications such as cleavage and phosphorylation. Recently, we showed that
galectin-3 Tyr-107 is phosphorylated by c-Abl; concomitantly, it was also shown that
galectin-3 can be cleaved at this site by
prostate-specific antigen (PSA), a
chymotrypsin-like
serine protease, after Tyr-107, resulting in loss of
galectin-3 multivalency while preserving its
carbohydrate binding activity.
Galectin-3 is largely a monomer in
solution but may form a homodimer by self-association through its
carbohydrate recognition domain, whereas, in the presence of a
ligand,
galectin-3 polymerizes up to pentamers utilizing its N-terminal domain. Oligomerization is a unique feature of secreted
galectin-3, which allows its function by forming ordered
galectin-
glycan structures, i.e. lattices, on the cell surface or through direct engagement of specific cell surface
glycoconjugates by traditional
ligand-receptor binding. We questioned whether Tyr-107 phosphorylation by c-Abl affects
galectin-3 cleavage by PSA. The data suggest a role for
galectin-3 in prostate cells associated with increased activity of c-Abl
kinase and loss of
phosphatase and
tensin homologue deleted on chromosome 10 (PTEN) activity. In addition, the ratio of phosphorylated/dephosphorylated
galectin-3 might be used as a complementary value to that of PSA for prognosis of
prostate cancer and a novel therapeutic target for the treatment of
prostate cancer.